ALMR — Alamar Biosciences, Inc.
—
Nasdaq ·
Unknown ·
Unknown ·
CIK 2104204 ·
Last close
$30.64
Market Cap
$2.13B
52W High
$39.61
52W Low
$18.85
ADV30
790,396
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 33,545,000 | 20,644,000 | -15,139,000 | -13,342,000 | 378,027,000 | 121,532,000 | 74,323,000 |
| Jun 2026 | 29,427,000 | 17,718,000 | -13,532,000 | -13,199,000 | 390,975,000 | 132,969,000 | 78,118,000 |
| Mar 2026 | 26,035,000 | 14,457,000 | -12,347,000 | -21,325,000 | 186,451,000 | 64,586,000 | 364,522,000 |
| Dec 2025 | 25,045,000 | 14,838,000 | -6,977,000 | -7,136,000 | 139,992,000 | 30,002,000 | 298,946,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-60,920,000
Investing CF
$-112,813,000
Financing CF
$247,781,000
CapEx
$-8,127,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.85
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-216,641,000
Inventory
$54,133,000
Receivables
$21,611,000
ST Investments
$105,053,000
EBIT TTM
$-53,490,000
Pretax Income TTM
$-54,312,000
Interest Exp TTM
$822,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$114,052,000
EBITDA
$-44,296,000
Free Cash Flow
—
Enterprise Value
$1,764,725,248
Total Cash
$226,584,992
Total Debt
$42,350,000
Shares Out
69,481,651
Trailing EPS
$-1.13
Book Value
$4.37
ROE
—
ROA
—
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 74,211,000 | -31,334,000 | -29,819,000 | 139,992,000 | 298,946,000 | -158,954,000 | -53,608,000 |
| Dec 2024 | 25,142,000 | -49,568,000 | -47,073,000 | 149,511,000 | 282,922,000 | -133,411,000 | -55,214,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$390,975,000
Forward EPS
$-0.12
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EBCRY | Embracer Group AB/ADR | $2.14B | $10.18 | — |
| NZF | Nuveen Municipal Credit Income Fund | $2.12B | $10.78 | — |
| MH | McGraw Hill, Inc. | $2.15B | $11.26 | — |
| WLY | JOHN WILEY & SONS, INC. | $2.10B | $50.17 | — |
| LB | LandBridge Corp | $2.10B | $70.81 | — |
News headlines (Yahoo Finance, 1h cache)
Alamar Biosciences Highlights NULISA Data in 46 Presentations at CTAD 2026, Including 10 Oral Presentations
2026-11-16 11:00 · Yahoo
Is GSK (LSE:GSK) A Bargain Following Its New Alamar Collaboration?
2026-11-13 00:18 · Yahoo
Why Is GSK (LSE:GSK) Drawing Attention For New Cancer Data And Proteomics?
2026-11-09 19:15 · Yahoo
Does Alamar Biosciences (ALMR) Sit Above Fair Value After The Selloff?
2026-11-05 13:13 · Yahoo
Alamar Biosciences to Participate in Upcoming Investor Conferences
2026-11-04 21:05 · Yahoo
Alamar Biosciences (ALMR) Q3 2026 Earnings Call Transcript
2026-11-04 16:32 · Yahoo
Alamar Biosciences (ALMR) Could Be 15% Undervalued On Q3 Results And Guidance
2026-11-04 08:12 · Yahoo
Alamar Biosciences Inc (ALMR) (Q3 2026) Earnings Call Highlights: Revenue Jumps 68% as Guidance ...
2026-11-04 05:10 · Yahoo
Alamar Biosciences Q3 Earnings Call Highlights
2026-11-04 00:14 · Yahoo
Alamar (ALMR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
2026-11-03 22:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.